Cybin Insiders Go All-In Before September Print

Cybin Inc. heads into its September 22 earnings event with one of the most concentrated insider buying clusters seen in a clinical-stage biotech this year.

Executive Chair Eric So and Chief Growth Officer Paul Glavine have together spent over $8.3 million buying shares in the open market across seven recorded trades since late August — none of it under a pre-arranged 10b5-1 plan. That discretionary detail matters. Both men filed Schedule 13D disclosures on September 9, each crossing the 5% ownership threshold at roughly 5.8% of shares outstanding. Two senior insiders simultaneously crossing the activist-disclosure threshold and spending eight-figure sums in the open market is one of the most unambiguous commitment signals available in public filings. Stakes are as last disclosed around the 5% threshold, and either holder could fall below that level without a further filing.

The stock, however, is not cooperating in the immediate run-up. HELP closed at $12.37 on September 18, down nearly 12% on the day and off 4.6% on the week — even as it remains roughly 6% higher on the month. Short interest at 6.0% of the free float is the one metric worth flagging in the lending market, though the borrow is anything but stressed: cost to borrow runs below 1% and availability is extraordinarily loose at over 3,700% of short interest, meaning there are far more shares available to lend than there are shorts borrowing them. The ORTEX short score of 38 sits in a mid-range band, consistent with a story driven by fundamental conviction rather than short-side pressure.

The bull-bear debate on Cybin centres almost entirely on clinical execution. Bulls point to the differentiated deuterated-psychedelic platform targeting MDD and GAD, a pipeline that the company and its backers argue offers faster onset and more durable effects than earlier-generation compounds — with recent M&A activity in the sector, notably Eli Lilly's acquisition of ATAI, cited as a read-through on strategic value. Barclays initiated coverage on September 18 with an Overweight rating, while TD Cowen maintained Buy and raised its target to $62 in August. The consensus target of $56.55 implies substantial upside from current levels, though Wells Fargo's July initiation at $16 — bracketing the current price — is a reminder that the analyst range is unusually wide, reflecting genuine disagreement on the clinical risk premium. HC Wainwright carried a target as high as $95 earlier in the year before cutting to $70 in July. Options positioning is not flashing alarm: the put/call ratio of 0.12 remains close to its 20-day average and well below the 52-week high of 0.24, suggesting no unusual demand for downside protection heading into the print.

The institutional register adds another dimension. Adage Capital and Millennium Management both built new or larger positions as of the June 30 reporting period. Venrock Healthcare holds roughly 9.9% on a 13G filed in November 2025, while Point72 trimmed sharply from 9.9% to 1.4% by May 2026. The most recent earnings reactions have been asymmetric on the upside — the August 18 event produced a 21% five-day gain — though the July 1 print produced a 5-day loss of similar magnitude, underscoring how binary the read-through has been.

The September 22 print will test whether the clinical progress Cybin's own insiders are betting on with their personal capital can outweigh the near-term price weakness that has greeted the announcement.